Digital Transformation of a Biopharma Quality Control Lab

Significance of the topic

The digital transformation of biopharma quality control laboratories is driven by stringent regulatory requirements and a need to improve operational efficiency. By replacing paper-based processes with integrated cloud-based solutions, labs can achieve faster turnaround times, better resource utilization, and enhanced data integrity.

Objectives and Study Overview

This study demonstrates the implementation of a fully digital workflow for monoclonal antibody (mAb) release testing in a small-scale biopharma quality control lab. The primary aim was to showcase end-to-end integration of a chromatography data system (OpenLab CDS) and a laboratory information management system (SLIMS) hosted on cloud infrastructure, covering steps from sample submission to final data archiving.

Methodology and Used Instrumentation

A network infrastructure on Microsoft Azure hosted separate OpenLab CDS and SLIMS servers, linked to local Agilent instruments via an Agilent instrument controller over the corporate network.

• LC-1 for aggregation analysis: Agilent 1290 Infinity II bio high-speed pump, multisampler with sample cooler, multicolumn thermostat with bio heat exchanger, diode array detector.
• LC-2 for charge variant analysis: Agilent 1290 Infinity II bio flexible pump, multisampler with sample cooler, multicolumn thermostat with bio heat exchanger, diode array detector.
• Software platforms: SLIMS 6.9, OpenLab CDS client/server 2.7, Sample Scheduler for OpenLab 2.7.

Main Results and Discussion

Visualized mobile phase preparation workflows in SLIMS minimized manual errors by guiding operators through weighing, dissolution, dilution, and mixing steps, while automatically updating inventory levels.
The integrated SLIMS–OpenLab interface allowed direct submission of test orders to chromatography instruments, enforcing standardized operating procedures and synchronized user access controls.
Two distinct mAb batches were analyzed in duplicate for aggregation and charge variants. Sample A01 complied with specifications (aggregate ≤1 % area, acidic variant 15–25 %, basic variant 10–15 %), whereas sample A02 exhibited out-of-specification acidic and basic variant levels, triggering warning flags and a rerun request.

Benefits and Practical Applications of the Method

• Streamlined digital workflow from sample request to data archiving.
• Real-time tracking of reagents, columns, and maintenance schedules.
• Automated enforcement of SOPs and secure user access control for improved data integrity.
• Reduced turnaround times and minimized operational disruptions.
• Centralized, versioned data storage for audit readiness and regulatory compliance.

Future Trends and Opportunities

Future advancements may include the integration of artificial intelligence for method optimization, machine learning-based predictive maintenance of instruments, blockchain-enabled data traceability, and expansion of cloud-native laboratory operations to support remote monitoring and collaborative research across sites.

Conclusion

The case study illustrates how a biopharma QC lab can transition to a fully digital ecosystem with minimal disruption. Seamless integration of cloud-based chromatography data and laboratory information management systems enhances efficiency, ensures regulatory compliance, and provides robust data management and traceability.

References

1. U.S. Food and Drug Administration. Facts About the Current Good Manufacturing Practices (CGMP).
2. International Conference on Harmonisation. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
3. Bian Y. Charge Variant and Aggregation Analysis of Innovator and Biosimilars of Rituximab. Agilent Technologies Application Note; Publication 5994-1496EN, 2019.